Moxifloxacino Cinfa (Moxifloxacin Hydrochloride)

Moxifloxacin Hydrochloride, the active ingredient in Moxifloxacino Cinfa, is a fluoroquinolone antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin and intra‑abdominal infections, in adult patients. It is indicated for community‑acquired bacterial pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, skin and skin structure infections, and intra‑abdominal infections in appropriate patients.

GNH USA supplies Moxifloxacino Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Moxifloxacino Cinfa is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.

- Community‑acquired bacterial pneumonia: eradicates susceptible pathogens causing lower‑respiratory‑tract infection. - Acute bacterial sinusitis: clears infection of the paranasal sinuses. - Acute exacerbations of chronic bronchitis: reduces bacterial load during flare‑ups. - Skin and skin structure infections: treats cellulitis, abscesses and other soft‑tissue infections. - Intra‑abdominal infections: combats mixed‑flora infections within the abdominal cavity.

Moxifloxacino Cinfa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Rash - Abdominal pain

Serious or Rare Side Effects: - Tendon rupture or tendinitis - QT interval prolongation leading to cardiac arrhythmia - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Clostridioides difficile‑associated colitis - Hepatic dysfunction - Peripheral neuropathy

Before prescribing Moxifloxacino Cinfa, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and adjust dose if necessary. - History of tendon disorders: avoid use in patients with prior tendon injury. - Cardiac risk: monitor ECG in patients with known QT prolongation or electrolyte disturbances. - Pregnancy and lactation: use only when benefits outweigh potential risks. - Concomitant medications: review for drugs that may increase toxicity or reduce efficacy. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Moxifloxacino Cinfa can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce oral absorption of moxifloxacin. - Systemic corticosteroids: increase risk of tendon rupture. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Other fluoroquinolones: additive risk of QT prolongation. - Theophylline: moxifloxacin can raise plasma theophylline levels. - Cyclosporine: increased risk of nephrotoxicity when combined.